Repurposing dopaminergic drugs for MS—the evidence mounts
F Marino, M Cosentino - Nature Reviews Neurology, 2016 - nature.com
Nature Reviews Neurology, 2016•nature.com
A new study has shown that both in patients with multiple sclerosis (MS) and in healthy
controls, dopamine inhibits production of IL-17 and IFN-γ by peripheral blood mononuclear
cells. The finding adds to previous evidence for the potential benefit of dopaminergic drugs
in MS.
controls, dopamine inhibits production of IL-17 and IFN-γ by peripheral blood mononuclear
cells. The finding adds to previous evidence for the potential benefit of dopaminergic drugs
in MS.
A new study has shown that both in patients with multiple sclerosis (MS) and in healthy controls, dopamine inhibits production of IL-17 and IFN-γ by peripheral blood mononuclear cells. The finding adds to previous evidence for the potential benefit of dopaminergic drugs in MS.
nature.com